UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 39

Sortiert nach

Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed

Journal of clinical oncology, 2002-01, Vol.20 (1), p.205-213

Keating, M. J.

2002

Volltextzugriff (PDF)

A phase Ib trial with MK-8628/OTX015, a small molecule inhibitor of bromodomain (BRD) and extra-terminal (BET) proteins, in patients with selected advanced solid tumors

European journal of cancer (1990), 2016-12, Vol.69, p.S2-S3

2016

Volltextzugriff (PDF)

Oxaliplatin: a new therapeutic option in colorectal cancer

Seminars in oncology, 1999-12, Vol.26 (6), p.647

1999

Volltextzugriff (PDF)

469 OTX015, a novel BET-bromodomain (BET-BRD) inhibitor, is a promising anticancer agent for human glioblastoma

European journal of cancer (1990), 2014-11, Vol.50, p.153-153

2014

Volltextzugriff (PDF)

587 Cellular pharmacokinetics and molecular pharmacodynamics studies of the BRD-BET inhibitor OTX015 in sensitive and resistant leukemic cell lines

European journal of cancer (1990), 2014-11, Vol.50, p.189-189

2014

Volltextzugriff (PDF)

567 OTX015, a BET-bromodomain (BET-BRD) inhibitor, potentiates the in vitro effects of chemotherapy drugs and targeted agents in human leukemic cell lines

European journal of cancer (1990), 2014-11, Vol.50, p.183-183

2014

Volltextzugriff (PDF)

565 Preclinical evaluation of OTX015, a novel BET-BRD inhibitor, on small cell lung cancer (SCLC) cell lines

European journal of cancer (1990), 2014-11, Vol.50, p.183-183

2014

Volltextzugriff (PDF)

580 Evaluation of the pan-BET-bromodomain inhibitor OTX015 as a single agent and in combination with everolimus (RAD001) in triple-negative breast cancer models

European journal of cancer (1990), 2014-11, Vol.50, p.187-187

2014

Volltextzugriff (PDF)

564 OTX015, a novel BET-BRD inhibitor is active in non-small-cell lung cancer cell (NSCLC) lines harboring different oncogenic mutations

European journal of cancer (1990), 2014-11, Vol.50, p.182-182

2014

Volltextzugriff (PDF)

Randomized Multicenter Phase II Study Comparing a Combination of Fluorouracil and Folinic Acid and Alternating Irinotecan and Oxaliplatin With Oxaliplatin and Irinotecan in Fluorouracil-Pretreated Metastatic Colorectal Cancer Patients

Journal of clinical oncology, 2001-11, Vol.19 (22), p.4195-4201

2001

Volltextzugriff (PDF)

Prognostic factors for survival in patients with brain metastases from renal cell carcinoma

Cancer, 1998-12, Vol.83 (12), p.2548-2553

1998

Volltextzugriff (PDF)

An open phase II trial of gemcitabine, oxaliplatin and vinorelbine combination as first-line therapy in advanced non-small cell lung cancer patients

Lung cancer (Amsterdam, Netherlands), 2009-02, Vol.63 (2), p.259-263

2009

Volltextzugriff (PDF)

Phase I and pharmacological study of an oxaliplatin and carboplatin combination in advanced malignancies

Annals of oncology, 2003-12, Vol.14 (12), p.1776-1782

2003

Volltextzugriff (PDF)

Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study

Annals of oncology, 2002, Vol.13 (1), p.103-107

2002

Volltextzugriff (PDF)

3LBA - A phase Ib trial with MK-8628/OTX015, a small molecule inhibitor of bromodomain (BRD) and extra-terminal (BET) proteins, in patients with selected advanced solid tumors

European journal of cancer (1990), 2016-12, Vol.69, p.S2-S3

2016

Volltextzugriff (PDF)

Phase I/II Study of Escalating Doses of Vinorelbine in Combination With Oxaliplatin in Patients With Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2001-01, Vol.19 (2), p.458-463

2001

Volltextzugriff (PDF)

943. Prognostic Determinants Associated with Efficacy of Adenoviral p53 Gene Therapy in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck

Molecular therapy, 2006-05, Vol.13 (S1), p.S364

2006

Volltextzugriff (PDF)

New possibilities in chemotherapy for colorectal cancer

Annals of oncology, 1999, Vol.10, p.105-111

1999

Volltextzugriff (PDF)

P08.63 Dose optimization of MK-8628 (OTX015), a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins, in patients with recurrent glioblastoma

Neuro-oncology (Charlottesville, Va.), 2016-10, Vol.18 (suppl_4), p.iv56-iv56

2016

Volltextzugriff (PDF)

Oxaliplatin for the treatment of advanced colorectal cancer: future directions

Seminars in oncology, 1998-04, Vol.25 (2 Suppl 5), p.47-53

1998

Volltextzugriff (PDF)

Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: The Institut Gustave Roussy experience

Cancer, 1996-03, Vol.77 (6), p.1193-1197

1996

Volltextzugriff (PDF)

Oxaliplatin clinical activity: a review

Critical reviews in oncology/hematology, 2000-08, Vol.35 (2), p.75-93

2000

Volltextzugriff (PDF)

Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients

Journal of cancer research and clinical oncology, 1999-12, Vol.125 (12), p.707-711

1999

Volltextzugriff (PDF)

Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed

Journal of clinical oncology, 2002, Vol.20 (1), p.205-213

2002

Volltextzugriff (PDF)

Treatment of Sarcomatoid Renal Cell Carcinoma: Is There a Role for Chemotherapy?

European urology, 1995, Vol.27 (2), p.138-141

1995

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(38)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed

A phase Ib trial with MK-8628/OTX015, a small molecule inhibitor of bromodomain (BRD) and extra-terminal (BET) proteins, in patients with selected advanced solid tumors

Oxaliplatin: a new therapeutic option in colorectal cancer

469 OTX015, a novel BET-bromodomain (BET-BRD) inhibitor, is a promising anticancer agent for human glioblastoma

587 Cellular pharmacokinetics and molecular pharmacodynamics studies of the BRD-BET inhibitor OTX015 in sensitive and resistant leukemic cell lines

567 OTX015, a BET-bromodomain (BET-BRD) inhibitor, potentiates the in vitro effects of chemotherapy drugs and targeted agents in human leukemic cell lines

565 Preclinical evaluation of OTX015, a novel BET-BRD inhibitor, on small cell lung cancer (SCLC) cell lines

580 Evaluation of the pan-BET-bromodomain inhibitor OTX015 as a single agent and in combination with everolimus (RAD001) in triple-negative breast cancer models

564 OTX015, a novel BET-BRD inhibitor is active in non-small-cell lung cancer cell (NSCLC) lines harboring different oncogenic mutations

Randomized Multicenter Phase II Study Comparing a Combination of Fluorouracil and Folinic Acid and Alternating Irinotecan and Oxaliplatin With Oxaliplatin and Irinotecan in Fluorouracil-Pretreated Metastatic Colorectal Cancer Patients

Prognostic factors for survival in patients with brain metastases from renal cell carcinoma

An open phase II trial of gemcitabine, oxaliplatin and vinorelbine combination as first-line therapy in advanced non-small cell lung cancer patients

Phase I and pharmacological study of an oxaliplatin and carboplatin combination in advanced malignancies

Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study

3LBA - A phase Ib trial with MK-8628/OTX015, a small molecule inhibitor of bromodomain (BRD) and extra-terminal (BET) proteins, in patients with selected advanced solid tumors

Phase I/II Study of Escalating Doses of Vinorelbine in Combination With Oxaliplatin in Patients With Advanced Non–Small-Cell Lung Cancer

943. Prognostic Determinants Associated with Efficacy of Adenoviral p53 Gene Therapy in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck

New possibilities in chemotherapy for colorectal cancer

P08.63 Dose optimization of MK-8628 (OTX015), a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins, in patients with recurrent glioblastoma

Oxaliplatin for the treatment of advanced colorectal cancer: future directions

Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: The Institut Gustave Roussy experience

Oxaliplatin clinical activity: a review

Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients

Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed

Treatment of Sarcomatoid Renal Cell Carcinoma: Is There a Role for Chemotherapy?

Suchergebnisse filtern